# 503716321 03/01/2016

# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT3762962

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
ROCHE DIAGNOSTICS GMBH	02/25/2016

#### **RECEIVING PARTY DATA**

Name:	Roche Diagnostics Operations, Inc.
Street Address:	9115 Hague Road
City:	Indianapolis
State/Country:	INDIANA
Postal Code:	46250

#### **PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	14970734

### **CORRESPONDENCE DATA**

**Fax Number:** (317)521-2883

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** 317-521-3104

Email: jackie.pike@roche.com
Correspondent Name: KENNETH J. WAITE
Address Line 1: 9115 HAGUE ROAD

Address Line 4: INDIANAPOLIS, INDIANA 46250

ATTORNEY DOCKET NUMBER: P31662-US-PD		
NAME OF SUBMITTER:	ER: KENNETH J. WAITE	
SIGNATURE:	/Kenneth J. Waite/	
DATE SIGNED:	03/01/2016	

**Total Attachments: 1** 

source=Assignment RDG-RDOI#page1.tif

PATENT 503716321 REEL: 037864 FRAME: 0033

## PATENT APPLICATION ASSIGNMENT

WHEREAS, Roche Diagnostics GmbH ("ASSIGNOR"), a German corporation having its principal office at Sandhofer Strasse 116, 68305 Mannheim, Germany, owns U. S. Patent Application Serial No. 14/970,734 filed December 16, 2015, entitled QUANTITATIVE CONTROL OF SIALYLATION AND SPECIFIC MONOSIALYLATION; and

WHEREAS, Roche Diagnostics Operations, Inc. ("ASSIGNEE"), a Delaware corporation, having its principal office at 9115 Hague Road, Indianapolis, Indiana 46250, United States of America, desires to acquire the entire right, title and interest in the Application;

NOW, THEREFORE, for good and valuable consideration paid to ASSIGNOR by ASSIGNEE, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR hereby assigns, sells and transfers all rights, title and interest in the Application, including any divisions, continuations, continuations-in-part, reexaminations, reissues, extensions, or other U. S. patent applications claiming the benefit of the filing date of the Application, to ASSIGNEE, its successors and assigns.

ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks to issue any United States Letters Patent which may issue for the Application, including any divisions, continuations, continuations-in-part, reexaminations, reissues or extensions thereof, to ASSIGNEE, its successors and assigns.

ASSIGNOR does hereby covenant and agree with ASSIGNEE, its successors and assigns, that ASSIGNOR will not execute any writing or do any act conflicting with this assignment, and that ASSIGNOR will execute such additional writings and do such additional acts as ASSIGNEE, its successors and assigns, may deem necessary or desirable to perfect its enjoyment of this assignment, and render all necessary assistance in making application for and obtaining original, divisional, continuation, continuation-in-part, reissued, reexamined or extended Letters Patent of the United States of America that may issue from the Application.

Roche Disonnetice GmbH

	STOCKE STREET
Date: February 25, 2016	Signature:
	Printed Name: Dr. Misera
	Title: Mandatory
Date: February 25, 2016	Signature: W. VWV Printed Name: Dr. Naser
	Title: Mandatory

RECORDED: 03/01/2016

PATENT REEL: 037864 FRAME: 0034